Korea's Celltrion Cuts Deal With Jordan-Based Hikma To Sell Its Biosimilars In The Middle East, Africa
This article was originally published in The Pink Sheet Daily
Executive Summary
Celltrion has been developing nine blockbuster biosimilar therapeutic antibodies in line with a bid to launch three in markets not protected with patent rights. The firm is moving to globally launch the biosimilars around 2011.